88 research outputs found

    Department of Health Sciences Research, Mayo Clinic

    Get PDF
    ABSTRACT Pathogenic variants in EBF3 were recently described in three back-to-back publications in association with a novel neurodevelopmental disorder characterized by intellectual disability, speech delay, ataxia, and facial dysmorphisms. In this report we describe an additional patient carrying a de novo show that our patient presents with phenotypes consistent with previously reported patients harboring EBF3 variants and expands the phenotypic spectrum of this newly identified disorder with the additional feature of a bicornuate uterus

    Hif1a inactivation rescues photoreceptor degeneration induced by a chronic hypoxia-like stress

    Get PDF
    Reduced choroidal blood flow and tissue changes in the ageing human eye impair oxygen delivery to photoreceptors and the retinal pigment epithelium. As a consequence, mild but chronic hypoxia may develop and disturb cell metabolism, function and ultimately survival, potentially contributing to retinal pathologies such as age-related macular degeneration (AMD). Here, we show that several hypoxia-inducible genes were expressed at higher levels in the aged human retina suggesting increased activity of hypoxia-inducible transcription factors (HIFs) during the physiological ageing process. To model chronically elevated HIF activity and investigate ensuing consequences for photoreceptors, we generated mice lacking von Hippel Lindau (VHL) protein in rods. This activated HIF transcription factors and led to a slowly progressing retinal degeneration in the ageing mouse retina. Importantly, this process depended mainly on HIF1 with only a minor contribution of HIF2. A gene therapy approach using AAV-mediated RNA interference through an anti-Hif1a shRNA significantly mitigated the degeneration suggesting a potential intervention strategy that may be applicable to human patients

    Clinical practice guidelines for the management of hypothyroidism

    Full text link

    2 1/2 Jahre Tb I-Therapie bei Lungentuberkulose

    No full text

    Entwicklungslinien chemotherapeutischer Forschung vom klinischen Standpunkt

    No full text

    Erfahrungsbericht über die Behandlung der Tuberkulose des Erwachsenen mit Isonicotinsäurchydrazid

    No full text
    corecore